Dove Medical Press

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results

Retrieved on: 
星期五, 三月 15, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Lung cancer, Ovarian cancer, B cell, Metastasis, Patient, City, CIRM, Virus, Cancer, Clinical trial, Supernova, Immune system, Patent, Dove Medical Press

Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.

Key Points: 
  • Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today reported its fourth quarter and full-year 2023 operating and financial results and reviewed recent business highlights.
  • “Calidi continues to make great progress across our development programs while continuing to innovate and expand our industry-leading position in cell-based immunotherapies,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Publicly announced novel systemic enveloped oncolytic virotherapy program, RTNova (CLD-400), targeting advanced solid tumors, including advanced metastatic disease.
  • General and administrative expenses were $16.0 million for the year ended December 31, 2023, compared to $15.9 million for the year ended December 31, 2022, respectively.

Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer

Retrieved on: 
星期一, 三月 11, 2024
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ovarian cancer, Regenerative medicine, Patient, City, CIRM, Woman, Neoplasm, Cancer, Safety, Division, FDA, Dove Medical Press, NSC, Pharmaceutical industry

CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.

Key Points: 
  • CLD-101 is the lead therapeutic candidate in Calidi’s NeuroNova program, comprising tumor-tropic neural stem cells (NSCs) that deliver an oncolytic adenovirus (NSC-CRAd-S-pk7) selectively to tumor sites.
  • This proposed CLD-101 treatment utilizes a neural stem cell line to deliver an oncolytic adenovirus directly to abdominal ovarian tumor sites.
  • In this trial, CLD-101 demonstrated safety and the stimulation of an anti-tumor response, with results published in Lancet Oncology .
  • Aboody has financial interest in and is a paid advisory board member for Calidi Biotherapeutics.

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

Retrieved on: 
星期一, 二月 12, 2024
Oncology, Health, Stem Cells, General Health, Pharmaceutical, Biotechnology, Immune system, Vaccinia, Neoplasm, Dove Medical Press, Cell, Conference, Supernova, Tumor microenvironment, Patient, Survival, Cancer, Vaccine

Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.

Key Points: 
  • Calidi's systemic enveloped virotherapy program, ImmunoNova, leverages extensive experience in utilizing cells to protect, potentiate and deliver virotherapies.
  • Utilizing an engineered and enveloped vaccinia virus, ImmunoNova shows promising potential in targeting advanced metastatic disease across the body, while maintaining survival in the bloodstream.
  • Preclinical models have demonstrated ImmunoNova's efficacy in transforming tumor immune microenvironments and eradicating distant and diverse tumors.
  • “Calidi's groundbreaking systemic enveloped virotherapy holds immense promise in revolutionizing the treatment landscape for cancer patients with advanced solid tumors.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
星期一, 一月 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

EZC Pak Declares Remarkable Results in Double-Blind Study, Including a 1.39-Day Reduction in Illness Duration for Patients with Upper Respiratory Infections

Retrieved on: 
星期三, 五月 3, 2023
Alternative Medicine, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Vitamins, Supplements, Infection, Dove Medical Press, URI, Observational study, Journal, Patient satisfaction, Public, Pak, Uris, COVID-19, Clinical trial, Research, Drug resistance, Lower respiratory tract infection, Vitamin D, Incidence, Infection and Drug Resistance, Rutgers University, Robert Wood Johnson Medical School, Common, Patient, NIH, Safety, Pharmaceutical industry

"EZC Pak was designed and formulated utilizing datasets in each component ingredient and then subsequently tested in an observational study.

Key Points: 
  • "EZC Pak was designed and formulated utilizing datasets in each component ingredient and then subsequently tested in an observational study.
  • This is the first double-blind randomized control trial — the gold standard in clinical research — comparing EZC Pak’s efficacy vs. placebo," said Dr. Sarath Malepati, creator of EZC Pak.
  • 120 patients were given EZC Pak, 60 were given EZC Pak + Vitamin D, and 180 were given the placebo.
  • Patients were asked to track and report their symptoms and vitals in an app-based journal immediately after first falling sick.

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

Retrieved on: 
星期五, 四月 21, 2023
Drug development, University, CMC, Cancer, Hope, Nebraska Medicine, University of Nebraska Medical Center, Infection, Dove Medical Press, Clinical Oncology, CMO, Bayer, Medical director, Patient, Corporation, Fudan University, Motivation, Global Medical Device Nomenclature, Growth, Therapy, Shanghai Medical College, Pharmaceutical industry, Medical device, Science

SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).

Key Points: 
  • SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointment of Dr. Oliver Kong as Chief Medical Officer (CMO).
  • Dr. Kong will be fully in charge of global clinical development and international collaboration of company pipelines, and participate in overall corporate strategy planning and implementation.
  • Dr. Kong holds a doctor's degree from Shanghai Medical College of Fudan University and a master's degree of Science in Molecular Immunology from University of Nebraska Medical Center.
  • Before joining ImmVira, he served as Chief Medical Officer and Corporate Vice President at Qilu Pharmaceuticals, Vice President of Clinical Oncology at Hengrui Therapeutics, Senior Global Medical Leader of Global Medical Affairs at Novartis Oncology, Senior Medical Director at Celegene and Medical Director of US Medical Affairs at Bayer HealthCare Pharmaceuticals.

Cancer Gene Therapy Global Market Report 2022: Sector to Reach $5.18 Billion by 2027 at a 19% CAGR

Retrieved on: 
星期一, 一月 23, 2023
Bone marrow, US Foods, Tata Memorial Centre, Immunotherapy, Death, Overalls, Dove Medical Press, Lung cancer, Multiple myeloma, Vector, Blood, DNA, Ferring Pharmaceuticals, Canadian Cancer Society, Government, Ageing, Cancer, Growth, Therapy, Prevalence, Indian Institutes of Technology, Breast cancer, Irish Cancer Society, World Health Organization, Patient, Food, Immune system, Bacillus, Investment, Neoplasm, Research, Pharmaceutical industry, Vaccine

The cancer gene therapy market is expected to grow at a CAGR of 19.0% over the forecast period to reach US$5.186 billion by 2027 from US$1.533 billion in 2020.

Key Points: 
  • The cancer gene therapy market is expected to grow at a CAGR of 19.0% over the forecast period to reach US$5.186 billion by 2027 from US$1.533 billion in 2020.
  • Cancer gene therapy refers to a medical technique for cancer treatment where a therapeutics DNA is introduced in the gene of a cancer patient which eliminates the cancer cell.
  • Owing to the rapidly growing prevalence of cancer, the demand for gene therapy products is also projected to increase, thereby boosting the cancer gene therapy market growth during the forecast period.
  • Based on therapy type, the cancer gene therapy market is segmented into immune cell gene therapy, oncolytic virotherapy, gene transfer, and others.

Cancer Gene Therapy Global Market Report 2022: Rapidly Rising Prevalence of Cancer Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
星期四, 一月 19, 2023
Biotechnology, General Health, Health, Genetics, Oncology, Bacillus, Chimeric antigen receptor T cell, Blood, Overalls, World Health Organization, Ageing, Ferring Pharmaceuticals, Neoplasm, Canadian Cancer Society, Lung cancer, Immunotherapy, Multiple myeloma, Government, DNA, Vector, Death, Immune system, Dove Medical Press, Growth, Food, Therapy, Lymphatic system, Patient, Prevalence, Bone marrow, Research, Cancer, Tata Memorial Centre, Indian Institute of Technology (BHU) Varanasi, US Foods, Breast cancer, Investment, Irish Cancer Society, Pharmaceutical industry, Vaccine

Cancer gene therapy refers to a medical technique for cancer treatment where a therapeutics DNA is introduced in the gene of a cancer patient which eliminates the cancer cell.

Key Points: 
  • Cancer gene therapy refers to a medical technique for cancer treatment where a therapeutics DNA is introduced in the gene of a cancer patient which eliminates the cancer cell.
  • Owing to the rapidly growing prevalence of cancer, the demand for gene therapy products is also projected to increase, thereby boosting the cancer gene therapy market growth during the forecast period.
  • Based on therapy type, the cancer gene therapy market is segmented into immune cell gene therapy, oncolytic virotherapy, gene transfer, and others.
  • Immunotherapy is expected to grow at a relatively higher rate during the forecast period of the cancer gene therapy market.

Calidi Biotherapeutics and First Light Acquisition Group (FLAG) Announce Merger Agreement to Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

Retrieved on: 
星期一, 一月 9, 2023
IND, Vaccinia, Form, HGG, Security (finance), Potyvirus, Cancer, CIRM, AML, WHO, Acute myeloid leukemia, California Institute for Regenerative Medicine, Regenerative medicine, NYSE American, FLAG, Safety, City of Hope, City, FDA, Food and Drug Administration, NYSE, Stem cell, Partnership, Dove Medical Press, Food, LLP, Patient, Supernova, PIPE, Investigational New Drug, Research, First Light, Interim, Acquisition, III, Weil, Gotshal & Manges, Bank, Vaccine, Pharmaceutical industry

LA JOLLA, Calif. and RESTON, Va., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”), a clinical-stage biotechnology company that is pioneering the development of allogeneic cell-based delivery of oncolytic viruses, and First Light Acquisition Group (“FLAG”) (NYSE American: FLAG), a special purpose acquisition company organized to acquire or merge with one or more businesses, today announced they have entered into a definitive merger agreement to create a public company focused on developing oncolytic viral therapies with stem cell-based delivery platforms to treat a wide range of cancers with significant unmet needs. Upon closing of the transaction, anticipated to occur in the second quarter of 2023, the combined company will be named Calidi Biotherapeutics, Inc. and led by Allan Camaisa, CEO and Chairman of the Board. In addition, the combined company’s common stock intends to list on the NYSE American under the ticker “CLDI.”

Key Points: 
  • “Our goal is to invest in people and technologies that address the most important priorities and to deliver results with national and global effect.
  • The parties will attempt to arrange a PIPE Investment from institutional investors of up to $40 million.
  • SuperNova (CLD-201): allogeneic adipose-derived mesenchymal stem cells (AD-MSC) loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors.
  • Additionally, Calidi expects interim results from a CLD-201 Phase 1 trial in the first half of 2024.

Proactive news headlines including Tempus Resources, Australian Strategic Materials, Blue Star Helium and Element 25

Retrieved on: 
星期一, 一月 9, 2023
Linda, Lithium, CXO, Zinc, Heart, Sempra Metals Ltd v IRC, SureFire, Dove Medical Press, Engineering, CPH, Uranium, Eveleigh, New South Wales, ASX, BNL, HEC, TMR, OTCQB, SLB, ATM, EPC, ADN, IMU, STM, DUN, RC, OTC, TSX, Main, Proactivity, AKM, Helium, Oil, Rare-earth element, Mining, Pharmaceutical industry, Obsidian, Battle of El Bramadero, Central West (New South Wales)

Click here

Key Points: 
  • Click here
    Blue Star Helium Ltd (ASX:BNL, OTC:BSNLF) has received the final approvals from the Colorado Oil and Gas Conservation Commission (COGCC) for drilling of four helium development wells at the Galactica/Pegasus Helium Project in Las Animas County, Colorado.
  • Click here
    Armada Metals Ltd (ASX:AMM) welcomes the renewal for an additional three years of permit G5-150 which forms part of its Nyanga Nickel-Copper Project in Gabon.
  • Click here
    Aspire Mining Ltd (ASX:AKM) continues to make progress with regulatory approvals for the world-class, wholly-owned Ovoot Coking Coal Project (OCCP) in northwest Mongolia.
  • Click here
    Imugene Ltd (ASX:IMU, OTC:IUGNF) has received Human Research Ethics Committee (HREC) approval to kick off an Australian Phase 1 clinical trial of its oncolytic virotherapy candidate, VAXINIA (CF33-hNIS).